カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の臨床試験用品市場（～2028年）：サービス別（製造、包装、物流）、フェーズ別、種類別（低分子、生物製剤）、治療領域別（がん、CVD、感染症、免疫学）、エンドユーザー別（製薬、バイオテクノロジー、CRO）、地域別

◆英語タイトル：Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases, Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology), End User (Pharma, Biotech, CROs), & Region - Global Forecast to 2028
	◆商品コード：PH3772-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年10月17日 ◆ページ数：328 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥742,500	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥997,500	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,222,500	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

"世界の臨床試験用品市場規模は2023年の39億米ドルから2028年には63億米ドルに達し、予測期間中の年平均成長率は9.9%と予測" 臨床試験数の増加、製品パイプラインの成長、臨床試験の分散化の進行などの要因が市場成長に好影響を与えそうです。

"臨床試験用品市場では、物流・流通分野が圧倒的なシェアを占める"
サービスに基づき、世界の臨床試験用品市場は病原体成分、アジュバント乳剤、微粒子アジュバント、サポニンベースのアジュバント、その他のアジュバントに区分されます。2022年の市場では、アジュバント乳剤セグメントが圧倒的なシェアを占めています。COVID-19およびその他の感染症におけるアジュバント乳剤の広範な使用、および伝染病の有病率の上昇は、市場の成長にプラスの影響を与えそうです。

"フェーズIIセグメントが2022年に最大シェアを占める"
フェーズに基づき、臨床試験用品市場はフェーズI、フェーズII、フェーズIII、フェーズIV、BA/BE試験に区分されます。2022年、第II相セグメントは臨床試験用品市場で最大のシェアを占めました。同セグメントは、臨床試験登録数の増加や、新がん治療薬開発のための製薬・バイオテクノロジー企業による研究開発投資の増加など、さまざまな要因により、市場で圧倒的なシェアを占めています。

"アジア太平洋地域は臨床試験用品市場でより速いペースで成長する可能性が高い"
臨床試験用品市場の地域は、北米、欧州、アジア太平洋地域、中南米、中東、アフリカに区分されます。アジア太平洋地域は予測期間中に大きなCAGRで成長すると予測されています。この地域の成長の主な原動力は、登録臨床試験数の増加です。中国、インド、日本では、臨床試験サービスを提供する有力企業が存在するため、臨床試験の分散化が進んでおり、アジア太平洋地域の市場成長を支えています。

本レポートのために実施した一次インタビューは以下のように分類されます：
- 回答者別供給側80％、需要側20%
- 回答者の役職別（供給側）管理職 - 45%、CXOおよび取締役 - 30%、経営幹部 - 25%
- 地域別北米 -40%、欧州 -25%、アジア太平洋地域 -20%、中南米 -10%、中東・アフリカ -5%

レポート掲載企業一覧
• Thermo Fisher Scientific Inc. (US)
• Catalent, Inc. (US)
• Eurofins (France)
• Piramal Pharma Solutions (India)
• PRA Health Sciences (Subsidiary of Icon Plc) (US)
• Marken (Subsidiary of UPS) (US)
• Parexel International (MA) Corporation (US)
• Biocair (UK)
• Almac Group (UK)
• Sharp Services, LLC (US)
• PCI Pharma Services (US)
• Nuvisan (Germany)
• Lonza Group (Switzerland)
• OCT Group LLC. (Latvia)
• Corex Logistics (Ireland)
• Acnos Pharma GMBH (Germany)
• Clinical Services International (UK)
• KLIFO A/S (Denmark)
• Clinigen Limited (UK)
• Ancillare LP (US)
• N-SIDE (Belgium)
• ADAllen Pharma (UK)
• Durbin ( Part of the Uniphar Group) (UK)
• Recipharm AB (Sweden)
• IPS Pharma (UK)

調査範囲
本レポートは臨床試験用品市場の詳細な情報を提供します。サービス、フェーズ、タイプ、治療分野、エンドユーザー、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、臨床試験用品市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、利害関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（製薬企業およびバイオ医薬品企業の研究開発費の増加、臨床試験件数の増加、臨床試験の分散化の進展、希少疾病および希少疾患の有病率の増加、アジア新興国におけるアウトソーシング活動の増加）、阻害要因（医薬品開発コストの高さ）、機会（新興市場における成長機会、生物製剤およびバイオシミラーの開発への投資の増加、専門的な試験サービスへの需要の高まり）、および課題（臨床試験コストの高さ）が臨床試験用品市場の成長に影響を及ぼしていることを分析します。
- サービスの開発/革新：臨床試験用品市場で新たに開始されたサービスに関する詳細な洞察を提供します。
- 市場開発：有利な市場に関する包括的な情報 - 本レポートは様々な地域の臨床試験用品市場を分析しています。
- 市場の多様化：臨床試験用品市場における新しいサービス、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- 競合評価：Thermo Fisher Scientific Inc. (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US), Parexel International (MA) Corporation (US), Biocair (UK), AlmacGroup (UK), Piramal Pharma Solutions (India), Sharp Services, LLC (US), PCI Pharma Services (US)などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価しています。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 臨床試験用品の世界市場：サービス別
7 臨床試験用品の世界市場：フェーズ別
8 臨床試験用品の世界市場：タイプ別
9 臨床試験用品の世界市場：治療領域別
10 臨床試験用品の世界市場：エンドユーザー別
11 臨床試験用品の世界市場：地域別
12 競争状況
13 企業情報
14 付録

❖ レポートの目次 ❖

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS & EXCLUSIONS 41
1.3 MARKET SCOPE 42
1.3.1 MARKETS COVERED 42
1.3.2 YEARS CONSIDERED 42
1.4 CURRENCY CONSIDERED 43
1.5 RESEARCH LIMITATIONS 43
1.6 STAKEHOLDERS 43
1.7 SUMMARY OF CHANGES 44
1.8 RECESSION IMPACT 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH APPROACH 45
FIGURE 1 RESEARCH DESIGN 45
2.1.1 PRIMARY RESEARCH 46
FIGURE 2 CLINICAL TRIAL SUPPLIES MARKET: PRIMARY RESPONDENTS 46
2.1.2 SECONDARY DATA 47
2.2 MARKET SIZE ESTIMATION 48
FIGURE 3 CLINICAL TRIAL SUPPLIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 48
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 49
2.2.1 INSIGHTS FROM PRIMARY 50
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY EXPERTS 50
2.2.2 SEGMENTAL ASSESSMENT (BY SERVICE, PHASE, TYPE, THERAPEUTIC AREA, END USER, AND REGION) 51
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 51
2.3 GROWTH RATE ASSUMPTIONS 52
FIGURE 7 CLINICAL TRIAL SUPPLIES MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 52
FIGURE 8 CLINICAL TRIAL SUPPLIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
FIGURE 9 DATA TRIANGULATION METHODOLOGY 54
2.4 STUDY ASSUMPTIONS 54
2.5 RISK ANALYSIS 55
2.6 RECESSION IMPACT ANALYSIS 55
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 56
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 56
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 56
3 EXECUTIVE SUMMARY 57
FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023 VS. 2028 (USD MILLION) 57
FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 58
FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 58
FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 59
FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023 VS. 2028 (USD MILLION) 59
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CLINICAL TRIAL SUPPLIES MARKET 60
4 PREMIUM INSIGHTS 61
4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW 61
FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 61
4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2022) 62
FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIAL SUPPLIES MARKET IN 2022 62
4.3 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY SERVICE, 2023 VS. 2028 63
FIGURE 18 LOGISTICS & DISTRIBUTION SERVICES TO CONTINUE TO DOMINATE MARKET IN 2028 63
4.4 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY END USER, 2022 63
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 63
4.5 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 64
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATES FROM 2023 TO 2028 64
5 MARKET OVERVIEW 65
5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 65
FIGURE 21 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 65
5.3 CLINICAL TRIAL SUPPLIES MARKET: IMPACT ANALYSIS 66
5.3.1 DRIVERS 66
5.3.1.1 Increasing R&D investments by biopharma companies 66
TABLE 4 R&D INVESTMENTS BY MAJOR PLAYERS (2022) 67
5.3.1.2 Growing number of clinical trials 67
FIGURE 22 NUMBER OF REGISTERED CLINICAL TRIALS (2011–2022) 67
FIGURE 23 ONGOING CLINICAL TRIALS, BY PHASE (% SHARE), 2022 68
5.3.1.3 Growing decentralization of clinical trials 68
5.3.1.4 Rising prevalence of orphan and rare diseases 69
FIGURE 24 OVERVIEW OF TOP 20 COMPANIES FOCUSING ON RARE DISEASES (AS OF 2023) 69
FIGURE 25 PERCENTAGE OF NEW ACTIVE SUBSTANCES LAUNCHED WITH ORPHAN DRUG DESIGNATION, 2012–2022 70
5.3.1.5 Increasing outsourcing activities in emerging Asian economies 70
5.3.2 RESTRAINTS 71
5.3.2.1 High cost of drug development 71
5.3.3 OPPORTUNITIES 72
5.3.3.1 Growth opportunities in emerging markets 72
5.3.3.2 Increased investments in development of biologics and biosimilars 72
FIGURE 26 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2015–2022) 73
TABLE 5 LIST OF BIOLOGICS APPROVED BY US FDA, 2022 73
FIGURE 27 BIOSIMILAR APPROVALS AND LAUNCHES (2015–2022) 74
5.3.3.3 Rising demand for specialized testing services 74
5.3.4 CHALLENGES 75
5.3.4.1 High cost of clinical trials 75
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
FIGURE 28 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS 75
5.5 PRICING ANALYSIS 76
5.5.1 INDICATIVE PRICING ANALYSIS OF OVERALL CLINICAL TRIALS, BY PHASE. 76
TABLE 6 PHASE III ONCOLOGY CLINICAL TRIAL COST (US AND EUROPEAN COUNTRIES) 77
TABLE 7 PHASE I ONCOLOGY CLINICAL TRIAL COST (SPAIN) 77
5.6 TECHNOLOGY ANALYSIS 78
5.6.1 INTERACTIVE RESPONSE TECHNOLOGY (IRT) 78
5.7 VALUE CHAIN ANALYSIS 79
FIGURE 29 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 79
5.8 ECOSYSTEM ANALYSIS 80
5.9 SUPPLY CHAIN ANALYSIS 81
TABLE 8 CLINICAL TRIAL SUPPLIES MARKET: SUPPLY CHAIN ANALYSIS 81
5.10 KEY CONFERENCES & EVENTS IN 2023–2024 82
TABLE 9 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 82
5.11 REGULATORY ANALYSIS 83
5.11.1 REGULATORY LANDSCAPE FOR CLINICAL TRIAL SUPPLIES 83
5.11.1.1 North America 83
5.11.1.2 Europe 84
5.11.1.3 Asia Pacific 84
5.11.1.4 Rest of the World 85
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
5.12 PORTER’S FIVE FORCES ANALYSIS 90
TABLE 15 CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS 90
5.12.1 THREAT OF NEW ENTRANTS 90
5.12.2 THREAT OF SUBSTITUTES 90
5.12.3 BARGAINING POWER OF SUPPLIERS 90
5.12.4 BARGAINING POWER OF BUYERS 91
5.12.5 DEGREE OF COMPETITION 91
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 92
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SUPPLY SERVICES 92
5.13.2 BUYING CRITERIA FOR CLINICAL TRIAL SUPPLY SERVICES 93
FIGURE 31 KEY BUYING CRITERIA FOR END USERS 93
6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE 94
6.1 INTRODUCTION 95
TABLE 16 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 95
6.2 LOGISTICS & DISTRIBUTION 95
6.2.1 INCREASING COMPLEXITY AND EVOLVING TREATMENT PROTOCOLS TO DRIVE DEMAND FOR LOGISTICS & DISTRIBUTION SERVICES 95
TABLE 17 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 18 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 19 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 20 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 21 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.3 STORAGE & RETENTION 98
6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH 98
TABLE 22 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 23 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 24 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 25 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 26 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.4 PACKAGING, LABELING, AND BLINDING 101
6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE SEGMENTAL GROWTH 101
TABLE 27 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 28 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 29 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 30 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 31 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LABELING, AND BLINDING SERVICES, COUNTRY, 2021–2028 (USD MILLION) 104
6.5 MANUFACTURING 104
6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING MANUFACTURING CAPACITIES TO DRIVE MARKET GROWTH 104
TABLE 32 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2021–2028 (USD MILLION) 105
TABLE 33 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 34 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 35 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 36 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, COUNTRY, 2021–2028 (USD MILLION) 107
6.6 COMPARATOR SOURCING 107
6.6.1 INTENSE MARKET COMPETITION AND RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH 107
TABLE 37 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 38 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 39 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 40 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 41 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.7 OTHER SERVICES 110
TABLE 42 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 43 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 44 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 45 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 46 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 113
7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE 114
7.1 INTRODUCTION 115
TABLE 47 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 115
7.2 PHASE III 115
7.2.1 LARGE PATIENT POPULATION ASSOCIATED WITH PHASE III TRIALS TO DRIVE DEMAND 115
TABLE 48 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 49 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 50 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 51 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 52 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 118
7.3 PHASE II 118
7.3.1 ABILITY OF PHASE II CLINICAL TRIALS TO PROVIDE CLARITY ON EFFECTIVENESS AND SAFETY OF DRUGS TO DRIVE MARKET GROWTH 118
TABLE 53 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 54 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 55 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 56 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 57 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 121
7.4 PHASE I 121
7.4.1 IMPORTANCE OF QUALITY CLINICAL TRIAL SUPPLIES IN PHASE I CLINICAL TRIALS TO BOOST MARKET 121
TABLE 58 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 59 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 60 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 61 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 62 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 123
7.5 PHASE IV 124
7.5.1 INCREASING NUMBER OF STUDIES UNDER PHASE IV TRIAL TO SUPPORT GROWTH 124
TABLE 63 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 64 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 65 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 66 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 67 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION) 126
7.6 BA/BE STUDIES 126
7.6.1 INCREASING PATENT EXPIRATION TO INCREASE DEMAND FOR BA/BE STUDIES 126
TABLE 68 CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 69 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 70 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 71 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 72 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION) 129
8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE 130
8.1 INTRODUCTION 131
TABLE 73 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
8.2 SMALL-MOLECULE DRUGS 131
8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET GROWTH 131
TABLE 74 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 75 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 76 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 77 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 78 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 134
8.3 BIOLOGIC DRUGS 134
8.3.1 RELATIVELY LOW RATE OF ATTRITION OF BIOLOGIC DRUGS COMPARED TO SMALL-MOLECULE DRUGS TO BOOST GROWTH 134
TABLE 79 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 80 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 81 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 82 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 83 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 137
8.4 MEDICAL DEVICES 137
8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO SUPPORT GROWTH 137
TABLE 84 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 85 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 86 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 87 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 88 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION) 140
9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA 141
9.1 INTRODUCTION 142
TABLE 89 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 142
9.2 ONCOLOGY 142
9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET GROWTH 142
FIGURE 32 US CANCER INCIDENCE IN MALES, BY TYPE (2022) 143
FIGURE 33 US CANCER INCIDENCE IN FEMALES, BY TYPE (2022) 143
FIGURE 34 GLOBAL ONCOLOGY-RELATED CLINICAL TRIALS, 2010–2021 (THOUSAND) 144
TABLE 90 NEW FDA-APPROVED ONCOLOGY DRUGS (2023) 145
TABLE 91 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 92 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 93 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 94 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 95 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 148
9.3 INFECTIOUS DISEASES 148
9.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ACCELERATE EFFORTS TO DEVELOP NEW DRUGS 148
TABLE 96 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 149
TABLE 97 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 98 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 99 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 100 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 151
9.4 NEUROLOGY 151
9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR NEUROLOGY RESEARCH TO DRIVE GROWTH 151
TABLE 101 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 152
TABLE 102 CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 152
TABLE 103 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 104 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 105 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 106 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 154
9.5 METABOLIC DISORDERS 155
9.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH 155
FIGURE 35 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 155
TABLE 107 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 156
TABLE 108 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 109 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 110 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 111 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 158
9.6 IMMUNOLOGY 159
9.6.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL DEMAND FOR CLINICAL TRIAL SUPPLIES 159
TABLE 112 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022) 159
TABLE 113 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 160
TABLE 114 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 115 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 116 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 117 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 162
9.7 CARDIOLOGY 162
9.7.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH 162
TABLE 118 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2023) 163
TABLE 119 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION) 164
TABLE 120 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 121 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 122 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 123 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 166
9.8 GENETIC & RARE DISEASES 166
9.8.1 INCREASING R&D FOR DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE DEMAND 166
TABLE 124 CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY REGION, 2021–2028 (USD MILLION) 167
TABLE 125 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 126 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 127 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 128 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 169
9.9 OTHER THERAPEUTIC AREAS 169
TABLE 129 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022) 170
TABLE 130 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 170
TABLE 131 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 132 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 133 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 134 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 172
10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER 173
10.1 INTRODUCTION 174
TABLE 135 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 174
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 174
10.2.1 INCREASING OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMA & BIOTECH COMPANIES TO BOOST MARKET 174
TABLE 136 CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 175
TABLE 137 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 138 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 139 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 140 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 177
10.3 CONTRACT RESEARCH ORGANIZATIONS 177
10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS 177
TABLE 141 CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 142 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 143 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 179
TABLE 145 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 179
10.4 MEDICAL DEVICE COMPANIES 179
10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET 179
TABLE 146 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2021–2028 (USD MILLION) 180
TABLE 147 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 148 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 149 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 150 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 182
11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION 183
11.1 INTRODUCTION 184
TABLE 151 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2021–2028 (USD MILLION) 184
11.2 NORTH AMERICA 184
FIGURE 36 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 185
TABLE 152 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 153 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 186
TABLE 154 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 186
TABLE 155 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 156 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 187
TABLE 157 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 188
11.2.1 US 188
11.2.1.1 Increasing R&D investments to drive market growth in US 188
TABLE 158 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 189
TABLE 159 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 189
TABLE 160 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 161 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 190
TABLE 162 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 191
11.2.2 CANADA 191
11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth 191
TABLE 163 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 192
TABLE 164 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 192
TABLE 165 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 166 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 193
TABLE 167 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 194
11.2.3 NORTH AMERICA: RECESSION IMPACT 194

11.3 EUROPE 195
TABLE 168 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 195
TABLE 169 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 196
TABLE 170 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 196
TABLE 171 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 172 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 197
TABLE 173 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 198
11.3.1 GERMANY 198
11.3.1.1 Growing number of sponsored trials to boost demand for clinical trial supplies in Germany 198
TABLE 174 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 199
TABLE 175 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 199
TABLE 176 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 177 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 200
TABLE 178 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 201
11.3.2 UK 201
11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth 201
TABLE 179 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 202
TABLE 180 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 202
TABLE 181 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 182 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 203
TABLE 183 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 204
11.3.3 FRANCE 204
11.3.3.1 Presence of leading pharmaceutical companies to support market growth in France 204
TABLE 184 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 205
TABLE 185 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 205
TABLE 186 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 187 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 206
TABLE 188 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 207
11.3.4 ITALY 207
11.3.4.1 Increasing number of drug approvals to drive market for clinical trial supplies in Italy 207
TABLE 189 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 207
TABLE 190 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 208
TABLE 191 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 208
TABLE 192 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209
TABLE 193 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 209
11.3.5 SPAIN 210
11.3.5.1 Increasing biologics production to support market growth in Spain 210
TABLE 194 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 210
TABLE 195 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 211
TABLE 196 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 197 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 212
TABLE 198 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 212
11.3.6 SWITZERLAND 213
11.3.6.1 Growing R&D efforts to provide growth opportunities for clinical trial supplies market in Switzerland 213
TABLE 199 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 213
TABLE 200 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 214
TABLE 201 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 202 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 215
TABLE 203 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 215
11.3.7 NETHERLANDS 216
11.3.7.1 Increasing pharmaceutical production to boost clinical trial supplies market in Netherlands 216
TABLE 204 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 216
TABLE 205 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 217
TABLE 206 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 207 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 218
TABLE 208 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 218
11.3.8 REST OF EUROPE 219
TABLE 209 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 220
TABLE 210 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 220
TABLE 211 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 212 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 221
TABLE 213 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 222
11.3.9 EUROPE: RECESSION IMPACT 222
11.4 ASIA PACIFIC 223
FIGURE 37 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 223
TABLE 214 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 224
TABLE 215 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 224
TABLE 216 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 225
TABLE 217 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 218 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 226
TABLE 219 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 226
11.4.1 CHINA 227
11.4.1.1 Favorable government regulations to boost market growth in China 227
TABLE 220 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 227
TABLE 221 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 228
TABLE 222 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 223 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 229
TABLE 224 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 229
11.4.2 JAPAN 230
11.4.2.1 Government initiatives for drug innovation to support market growth 230
TABLE 225 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 231
TABLE 226 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 231
TABLE 227 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 228 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 232
TABLE 229 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 233
11.4.3 INDIA 233
11.4.3.1 Low manufacturing costs and skilled workforce to attract outsourcing and investments to India 233
TABLE 230 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 234
TABLE 231 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 234
TABLE 232 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 233 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 235
TABLE 234 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 236
11.4.4 AUSTRALIA 236
11.4.4.1 Presence of many research institutes conducting clinical trials to boost market growth 236
TABLE 235 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 237
TABLE 236 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 237
TABLE 237 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 238 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 238
TABLE 239 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 239
11.4.5 SOUTH KOREA 239
11.4.5.1 Government investments to contribute to market growth in South Korea 239
TABLE 240 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 240
TABLE 241 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 240
TABLE 242 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 243 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 241
TABLE 244 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 242
11.4.6 SINGAPORE 242
11.4.6.1 Presence of world-class infrastructure to drive market growth in Singapore 242
TABLE 245 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 242
TABLE 246 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 243
TABLE 247 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 248 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 244
TABLE 249 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 244
11.4.7 REST OF ASIA PACIFIC 245
TABLE 250 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 245
TABLE 251 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 245
TABLE 252 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 253 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 246
TABLE 254 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 247
11.4.8 ASIA PACIFIC: RECESSION IMPACT 247
11.5 LATIN AMERICA 248
TABLE 255 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 248
TABLE 256 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2021–2028 (USD MILLION) 249
TABLE 257 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 250
TABLE 258 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 259 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 251
TABLE 260 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 251
11.5.1 BRAZIL 252
11.5.1.1 Growth in pharmaceutical R&D to support market growth 252
TABLE 261 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 252
TABLE 262 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 253
TABLE 263 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 264 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 254
TABLE 265 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 254
11.5.2 MEXICO 255
11.5.2.1 Growing number of Phase III clinical trials to drive market growth 255
TABLE 266 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 255
TABLE 267 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 256
TABLE 268 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 269 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 257
TABLE 270 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 257
11.5.3 REST OF LATIN AMERICA 258
TABLE 271 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 258
TABLE 272 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 258
TABLE 273 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 274 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 259
TABLE 275 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 260
11.5.4 LATIN AMERICA: RECESSION IMPACT 260
11.6 MIDDLE EAST 261
11.6.1 GROWING PRESENCE OF PHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH 261
TABLE 276 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 261
TABLE 277 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 262
TABLE 278 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 279 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 263
TABLE 280 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 263
11.6.2 MIDDLE EAST: RECESSION IMPACT 264
11.7 AFRICA 264
11.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH 264
TABLE 281 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 265
TABLE 282 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 265
TABLE 283 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 266
TABLE 284 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 266
TABLE 285 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 267
11.7.2 AFRICA: RECESSION IMPACT 267
12 COMPETITIVE LANDSCAPE 268
12.1 INTRODUCTION 268
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 269
FIGURE 38 CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 269
12.3 REVENUE SHARE ANALYSIS 270
FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022) 270
12.4 MARKET SHARE ANALYSIS 271
FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 271
TABLE 286 CLINICAL TRIAL SUPPLIES MARKET: DEGREE OF COMPETITION 272
12.5 COMPANY EVALUATION MATRIX 272
FIGURE 41 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 273
12.5.1 STARS 273
12.5.2 EMERGING LEADERS 274
12.5.3 PERVASIVE PLAYERS 274
12.5.4 PARTICIPANTS 274
12.6 COMPANY FOOTPRINT 274
12.6.1 SERVICE FOOTPRINT OF TOP 25 COMPANIES 274
TABLE 287 CLINICAL TRIAL SUPPLIES MARKET: COMPANY SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS 274
12.6.2 REGIONAL FOOTPRINT OF TOP 25 COMPANIES 276
TABLE 288 CLINICAL TRIAL SUPPLIES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 276
12.7 COMPANY EVALUATION MATRIX: START-UPS/SMES 277
FIGURE 42 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 277
12.7.1 PROGRESSIVE COMPANIES 277
12.7.2 STARTING BLOCKS 278
12.7.3 RESPONSIVE COMPANIES 278
12.7.4 DYNAMIC COMPANIES 278
12.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 278
TABLE 289 CLINICAL TIAL SUPPLIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 278
TABLE 290 CLINICAL TRIAL SUPPLIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS 279
12.9 COMPETITIVE SCENARIO AND TRENDS 280
12.9.1 SERVICES LAUNCHES & APPROVALS 280
TABLE 291 CLINICAL TRIAL SUPPLIES MARKET: SERVICE LAUNCHES, JANUARY 2021–AUGUST 2023 280
12.9.2 DEALS 280
TABLE 292 CLINICAL TRIAL SUPPLIES MARKET: DEALS, JANUARY 2021–JULY 2023 280
12.9.3 OTHER DEVELOPMENTS 282
TABLE 293 CLINICAL TRIAL SUPPLIES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2023 282

13 COMPANY PROFILES 283
(Business overview, Services offered, Recent Developments, MNM view)*
13.1 KEY MARKET PLAYERS 283
13.1.1 THERMO FISHER SCIENTIFIC, INC. 283
TABLE 294 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 283
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 284
13.1.2 CATALENT, INC. 289
TABLE 295 CATALENT, INC.: BUSINESS OVERVIEW 289
FIGURE 44 CATALENT, INC.: COMPANY SNAPSHOT (2022) 290
13.1.3 EUROFINS SCIENTIFIC 295
TABLE 296 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 295
FIGURE 45 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 296
13.1.4 PIRAMAL PHARMA SOLUTIONS 298
TABLE 297 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW 298
FIGURE 46 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022) 299
13.1.5 PRA HEALTH SCIENCES (A SUBSIDIARY OF ICON PLC) 301
TABLE 298 PRA HEALTH SCIENCES: BUSINESS OVERVIEW 301
FIGURE 47 ICON PLC: COMPANY SNAPSHOT (2022) 302
13.1.6 MARKEN (A SUBSIDIARY OF UPS) 304
TABLE 299 UPS: BUSINESS OVERVIEW 304
FIGURE 48 UPS: COMPANY SNAPSHOT (2022) 305
13.1.7 PAREXEL INTERNATIONAL (MA) CORPORATION 307
TABLE 300 PAREXEL INTERNATIONAL (MA) CORPORATION: BUSINESS OVERVIEW 307
13.1.8 BIOCAIR 310
TABLE 301 BIOCAIR: BUSINESS OVERVIEW 310
13.1.9 ALMAC GROUP 312
TABLE 302 ALMAC GROUP: BUSINESS OVERVIEW 312
13.1.10 SHARP SERVICES, LLC 314
TABLE 303 SHARP SERVICES, LLC: BUSINESS OVERVIEW 314
13.1.11 PCI PHARMA SERVICES 315
TABLE 304 PCI PHARMA SERVICES: BUSINESS OVERVIEW 315
13.1.12 NUVISAN 317
TABLE 305 NUVISAN: BUSINESS OVERVIEW 317
13.1.13 LONZA GROUP 319
TABLE 306 LONZA GROUP: BUSINESS OVERVIEW 319
FIGURE 49 LONZA GROUP: COMPANY SNAPSHOT (2022) 320
13.2 OTHER PLAYERS 321
13.2.1 OCT GROUP LLC 321
13.2.2 COREX LOGISTICS LIMITED 322
13.2.3 ACNOS PHARMA GMBH 323
13.2.4 CLINICAL SERVICES INTERNATIONAL 324
13.2.5 KLIFO 325
13.2.6 CLINIGEN LIMITED 326
13.2.7 ANCILLARE LP 327
13.2.8 N-SIDE 328
13.2.9 ADALLEN PHARMA 329
13.2.10 DURBIN 330
13.2.11 RECIPHARM AB 331
13.2.12 IPS PHARMA 332
*Details on Business overview, Services offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 333
14.1 DISCUSSION GUIDE 333
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 337
14.3 CUSTOMIZATION OPTIONS 339
14.4 RELATED REPORTS 339
14.5 AUTHOR DETAILS 340

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の臨床試験用品市場（～2028年）：サービス別（製造、包装、物流）、フェーズ別、種類別（低分子、生物製剤）、治療領域別（がん、CVD、感染症、免疫学）、エンドユーザー別（製薬、バイオテクノロジー、CRO）、地域別(Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases, Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology), End User (Pharma, Biotech, CROs), & Region - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp